Press Releases

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
December 18, 2023
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
December 13, 2023
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
November 13, 2023
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 8, 2023
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
November 7, 2023
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
November 6, 2023
Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
October 26, 2023
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2023
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer
October 14, 2023
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 6, 2023